| Carol R Parks, MD | |
|
3158 Smokies Edge Road, Sevierville, TN 37862 | |
| (865) 429-2331 | |
| Not Available |
| Full Name | Carol R Parks |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 31 Years |
| Location | 3158 Smokies Edge Road, Sevierville, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538116132 | NPI | - | NPPES |
| 4131273 | Other | TN | BCBS OF TENNESSEE |
| PENDING | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD40622 (Tennessee) | Primary |
| 207P00000X | Emergency Medicine | MD17573 (Alabama) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Hospital | Mobile, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Compass Providence Urgent Care Lllp | 3375865934 | 7 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.
In a paper published this week in the open-access journal PLoS Medicine Frits Rosendaal and colleagues from Leiden University Medical Center, Academic Medical Center Amsterdam and Nestle Medical Services, provide the first absolute estimate of risk of venous thrombosis after air travel.
Two years ago, 57-year-old Allus Brown underwent a simultaneous heart-kidney transplant and spent months in and out of the hospital after battling dilated cardiomyopathy, a condition that enlarges and weakens the heart. Now fully recovered, Brown is still in and out of Northwestern Memorial Hospital's Bluhm Cardiovascular Institute each week. Only nowadays when he visits, he's laughing it up, playing board games, and sharing accounts of his own struggles with heart disease as part of the Bluhm Institute's new and innovative program, SMART Heart, stress management and recreational therapy for heart patients.
Few researchers doubt the potential for nanoparticles to revolutionize the way anticancer drugs and imaging agents are delivered to tumors.
› Verified 7 days ago
| Entity Name | Compass Urgent Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295028082 PECOS PAC ID: 8820269871 Enrollment ID: O20110922000432 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.
In a paper published this week in the open-access journal PLoS Medicine Frits Rosendaal and colleagues from Leiden University Medical Center, Academic Medical Center Amsterdam and Nestle Medical Services, provide the first absolute estimate of risk of venous thrombosis after air travel.
Two years ago, 57-year-old Allus Brown underwent a simultaneous heart-kidney transplant and spent months in and out of the hospital after battling dilated cardiomyopathy, a condition that enlarges and weakens the heart. Now fully recovered, Brown is still in and out of Northwestern Memorial Hospital's Bluhm Cardiovascular Institute each week. Only nowadays when he visits, he's laughing it up, playing board games, and sharing accounts of his own struggles with heart disease as part of the Bluhm Institute's new and innovative program, SMART Heart, stress management and recreational therapy for heart patients.
Few researchers doubt the potential for nanoparticles to revolutionize the way anticancer drugs and imaging agents are delivered to tumors.
› Verified 7 days ago
| Entity Name | App Of Alabama Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659646040 PECOS PAC ID: 3577725068 Enrollment ID: O20120430000174 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.
In a paper published this week in the open-access journal PLoS Medicine Frits Rosendaal and colleagues from Leiden University Medical Center, Academic Medical Center Amsterdam and Nestle Medical Services, provide the first absolute estimate of risk of venous thrombosis after air travel.
Two years ago, 57-year-old Allus Brown underwent a simultaneous heart-kidney transplant and spent months in and out of the hospital after battling dilated cardiomyopathy, a condition that enlarges and weakens the heart. Now fully recovered, Brown is still in and out of Northwestern Memorial Hospital's Bluhm Cardiovascular Institute each week. Only nowadays when he visits, he's laughing it up, playing board games, and sharing accounts of his own struggles with heart disease as part of the Bluhm Institute's new and innovative program, SMART Heart, stress management and recreational therapy for heart patients.
Few researchers doubt the potential for nanoparticles to revolutionize the way anticancer drugs and imaging agents are delivered to tumors.
› Verified 7 days ago
| Entity Name | Northwest Emergency Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205197951 PECOS PAC ID: 8628224425 Enrollment ID: O20120810000153 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.
In a paper published this week in the open-access journal PLoS Medicine Frits Rosendaal and colleagues from Leiden University Medical Center, Academic Medical Center Amsterdam and Nestle Medical Services, provide the first absolute estimate of risk of venous thrombosis after air travel.
Two years ago, 57-year-old Allus Brown underwent a simultaneous heart-kidney transplant and spent months in and out of the hospital after battling dilated cardiomyopathy, a condition that enlarges and weakens the heart. Now fully recovered, Brown is still in and out of Northwestern Memorial Hospital's Bluhm Cardiovascular Institute each week. Only nowadays when he visits, he's laughing it up, playing board games, and sharing accounts of his own struggles with heart disease as part of the Bluhm Institute's new and innovative program, SMART Heart, stress management and recreational therapy for heart patients.
Few researchers doubt the potential for nanoparticles to revolutionize the way anticancer drugs and imaging agents are delivered to tumors.
› Verified 7 days ago
| Entity Name | Southern Alabama Physicians, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467701490 PECOS PAC ID: 0345499562 Enrollment ID: O20121003000896 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.
In a paper published this week in the open-access journal PLoS Medicine Frits Rosendaal and colleagues from Leiden University Medical Center, Academic Medical Center Amsterdam and Nestle Medical Services, provide the first absolute estimate of risk of venous thrombosis after air travel.
Two years ago, 57-year-old Allus Brown underwent a simultaneous heart-kidney transplant and spent months in and out of the hospital after battling dilated cardiomyopathy, a condition that enlarges and weakens the heart. Now fully recovered, Brown is still in and out of Northwestern Memorial Hospital's Bluhm Cardiovascular Institute each week. Only nowadays when he visits, he's laughing it up, playing board games, and sharing accounts of his own struggles with heart disease as part of the Bluhm Institute's new and innovative program, SMART Heart, stress management and recreational therapy for heart patients.
Few researchers doubt the potential for nanoparticles to revolutionize the way anticancer drugs and imaging agents are delivered to tumors.
› Verified 7 days ago
| Entity Name | Alabama Emergency Physician Partners, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891031894 PECOS PAC ID: 4082868641 Enrollment ID: O20130206000466 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.
In a paper published this week in the open-access journal PLoS Medicine Frits Rosendaal and colleagues from Leiden University Medical Center, Academic Medical Center Amsterdam and Nestle Medical Services, provide the first absolute estimate of risk of venous thrombosis after air travel.
Two years ago, 57-year-old Allus Brown underwent a simultaneous heart-kidney transplant and spent months in and out of the hospital after battling dilated cardiomyopathy, a condition that enlarges and weakens the heart. Now fully recovered, Brown is still in and out of Northwestern Memorial Hospital's Bluhm Cardiovascular Institute each week. Only nowadays when he visits, he's laughing it up, playing board games, and sharing accounts of his own struggles with heart disease as part of the Bluhm Institute's new and innovative program, SMART Heart, stress management and recreational therapy for heart patients.
Few researchers doubt the potential for nanoparticles to revolutionize the way anticancer drugs and imaging agents are delivered to tumors.
› Verified 7 days ago
| Entity Name | Compass Providence Urgent Care Lllp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770997579 PECOS PAC ID: 3375865934 Enrollment ID: O20141210000235 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.
In a paper published this week in the open-access journal PLoS Medicine Frits Rosendaal and colleagues from Leiden University Medical Center, Academic Medical Center Amsterdam and Nestle Medical Services, provide the first absolute estimate of risk of venous thrombosis after air travel.
Two years ago, 57-year-old Allus Brown underwent a simultaneous heart-kidney transplant and spent months in and out of the hospital after battling dilated cardiomyopathy, a condition that enlarges and weakens the heart. Now fully recovered, Brown is still in and out of Northwestern Memorial Hospital's Bluhm Cardiovascular Institute each week. Only nowadays when he visits, he's laughing it up, playing board games, and sharing accounts of his own struggles with heart disease as part of the Bluhm Institute's new and innovative program, SMART Heart, stress management and recreational therapy for heart patients.
Few researchers doubt the potential for nanoparticles to revolutionize the way anticancer drugs and imaging agents are delivered to tumors.
› Verified 7 days ago
| Entity Name | Northwest Alabama Emergency Medicine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639692767 PECOS PAC ID: 0749556611 Enrollment ID: O20171019003017 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.
In a paper published this week in the open-access journal PLoS Medicine Frits Rosendaal and colleagues from Leiden University Medical Center, Academic Medical Center Amsterdam and Nestle Medical Services, provide the first absolute estimate of risk of venous thrombosis after air travel.
Two years ago, 57-year-old Allus Brown underwent a simultaneous heart-kidney transplant and spent months in and out of the hospital after battling dilated cardiomyopathy, a condition that enlarges and weakens the heart. Now fully recovered, Brown is still in and out of Northwestern Memorial Hospital's Bluhm Cardiovascular Institute each week. Only nowadays when he visits, he's laughing it up, playing board games, and sharing accounts of his own struggles with heart disease as part of the Bluhm Institute's new and innovative program, SMART Heart, stress management and recreational therapy for heart patients.
Few researchers doubt the potential for nanoparticles to revolutionize the way anticancer drugs and imaging agents are delivered to tumors.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carol R Parks, MD Po Box 5470, Sevierville, TN 37864-5470 Ph: (865) 429-2331 | Carol R Parks, MD 3158 Smokies Edge Road, Sevierville, TN 37862 Ph: (865) 429-2331 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company's two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome, or IBS-d. Both studies met their target enrollments and Furiex expects to release top line results in the first quarter of 2014.
In a paper published this week in the open-access journal PLoS Medicine Frits Rosendaal and colleagues from Leiden University Medical Center, Academic Medical Center Amsterdam and Nestle Medical Services, provide the first absolute estimate of risk of venous thrombosis after air travel.
Two years ago, 57-year-old Allus Brown underwent a simultaneous heart-kidney transplant and spent months in and out of the hospital after battling dilated cardiomyopathy, a condition that enlarges and weakens the heart. Now fully recovered, Brown is still in and out of Northwestern Memorial Hospital's Bluhm Cardiovascular Institute each week. Only nowadays when he visits, he's laughing it up, playing board games, and sharing accounts of his own struggles with heart disease as part of the Bluhm Institute's new and innovative program, SMART Heart, stress management and recreational therapy for heart patients.
Few researchers doubt the potential for nanoparticles to revolutionize the way anticancer drugs and imaging agents are delivered to tumors.
› Verified 7 days ago
Dr. Kenneth Neil Shaw, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 709 Middle Creek Rd, Sevierville, TN 37862 Phone: 865-453-7111 | |
Edmund Joseph Timpano, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 742 Middle Creek Rd, Sevierville, TN 37862 Phone: 865-466-7000 | |
Dr. Charise Bowman Johns, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 709 Middle Creek Rd, Sevierville, TN 37862 Phone: 865-429-6625 | |
Mary Frances Dukes, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 742 Middle Creek Rd, Sevierville, TN 37862 Phone: 865-446-7000 | |
Dr. Evann Max Herrell, D.O. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 742 Middle Creek Rd, Sevierville, TN 37862 Phone: 865-446-7000 | |
Zeke Oliver, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 742 Middle Creek Rd, Sevierville, TN 37862 Phone: 865-446-7000 |